We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Smith & Nephew Warned on Recall Notification, GMP Deficiencies

Smith & Nephew Warned on Recall Notification, GMP Deficiencies

August 1, 2014

The FDA has warned Smith & Nephew for failing to report a recall of the Renasys soft port dressing, which is used with its Renasys line of negative pressure wound treatment devices.

In March 2013, the company distributed a bulletin to users notifying them of changes to the dressing design. The modifications were made after Smith & Nephew found that improper installation of the filter could result in failure to activate the full/blockage alarm, according to the June 11 warning letter published online. The company neither notified the FDA nor provided written justification for not doing so, the letter says.

Smith & Nephew’s Saint Petersburg, Fla., facility also found that the alarm function could be affected by small amounts of air leakage and changed the instructions for inserting the Renasys EZ and EZ Plus Pumps canister filter, as well as the maintenance instructions for the O-ring of the Renasys Go. However, the company could not provide documentation of effectiveness checks for these corrective and preventive actions.

Meanwhile, the devicemaker failed to evaluate the impact of decreasing the sensitivity of the leak alarm for the Renasys Go Pump on the device’s risk-assessment records.

Smith & Nephew’s corrective action procedure did not require verification or validation of the CAPA to ensure it is effective and does not adversely affect the finished device, the warning letter says.

The FDA investigator also noted that Smith & Nephew did not use people who represent potential users of the device to perform testing for validation of a change to the canister filter and an updated version of the installation instructions. And the company did not perform a risk-benefit assessment for the individual hazard of exsanguination for negative pressure wound treatment devices, even though this is listed in the risk-assessment record for devices with a final residual risk of “medium.”

Additional citations relate to complaint handling, as the company’s procedure did not require an appropriate statistical methodology to detect recurring quality problems, the letter says. Smith & Nephew had not maintained a section of its procedure that required a risk-assessment review for complaints that are either adverse events or could lead to a potential hazard.

The FDA investigator reviewed 17 complaint records on alleged pooling and/or lack of alarm function for the Renasys EZ/EZ Plus device where the company documented known hazards, finding that 10 did not show a review of the risk assessment for the device.

The FDA also advised the company that certain design enhancements would require new 510(k) clearance, leading Smith & Nephew to temporarily halt commercial distribution of the Renasys product line in the U.S.

“The applications for clearance have now been filed and are awaiting action,” Smith & Nephew said, adding that the company is working with the FDA to address other concerns.

Many firms are complacent about recalls — and woefully unprepared. Make sure your company’s recall plan is up to date by purchasing Recall Management for Medical Devices.

Medical Devices Regulatory Affairs Postmarket Safety

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • CE mark

    MiRXES Earns CE Mark for COVID-19/Flu Test

  • KitePharma_Logo

    Kite Pharma’s Tecartus Gains UK Recommendation for Lymphoma

  • Eli Lilly logo

    Lilly’s Monoclonal Antibody Could Prevent COVID-19 in the Elderly

  • CE mark

    Fluidigm Gains CE Mark for Saliva-Based Assay for COVID-19

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing